Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 348

1.

Priority Considerations for Medicinal Cannabis-Related Research.

Bonn-Miller MO, Pollack CV Jr, Casarett D, Dart R, ElSohly M, Good L, Guzmán M, Hanuš L, Hill KP, Huestis MA, Marsh E, Sisley S, Skinner N, Spahr J, Vandrey R, Viscusi E, Ware MA, Abrams D.

Cannabis Cannabinoid Res. 2019 Sep 23;4(3):139-157. doi: 10.1089/can.2019.0045. eCollection 2019. No abstract available.

PMID:
31579832
2.

Medication Errors from Over-the-Counter Cough and Cold Medications in Children.

Wang GS, Reynolds KM, Banner W, Bond GR, Kauffman RE, Palmer RB, Paul IM, Rapp-Olsson M, Green JL, Dart RC.

Acad Pediatr. 2019 Sep 25. pii: S1876-2859(19)30389-4. doi: 10.1016/j.acap.2019.09.006. [Epub ahead of print]

PMID:
31562931
3.

Non-medical use of loperamide in the UK and USA.

Webb NE, Wood DM, Black JC, Amioka E, Dart RC, Dargan PI.

QJM. 2019 Aug 19. pii: hcz215. doi: 10.1093/qjmed/hcz215. [Epub ahead of print]

PMID:
31424512
4.

Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and Prevention.

Kertesz SG, Satel SL, DeMicco J, Dart RC, Alford DP.

Subst Abus. 2019 Jul 30:1-3. doi: 10.1080/08897077.2019.1635973. [Epub ahead of print]

PMID:
31361588
5.

Nonmedical use of alprazolam in the UK: Results from a nationally representative survey.

Hockenhull J, Amioka E, Black JC, Haynes CM, Dargan PI, Dart RC, Wood DM.

Br J Clin Pharmacol. 2019 Aug;85(8):1841-1845. doi: 10.1111/bcp.13959. Epub 2019 Jun 5.

PMID:
31165490
6.

Future use of the European Society of Hypertension International Protocol for validation of automated sphygmomanometers.

Alpert BS, Sarkis J, Dart RA, Quinn D, Friedman B, Townsend RR, Shimbo D.

Blood Press Monit. 2019 Aug;24(4):161-162. doi: 10.1097/MBP.0000000000000390. No abstract available.

PMID:
31116154
7.

Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and Prevention.

Kertesz SG, Satel SL, DeMicco J, Dart RC, Alford DP.

Subst Abus. 2019;40(1):4-6. doi: 10.1080/08897077.2019.1613830. Epub 2019 May 17. No abstract available.

PMID:
31100051
8.

Adverse events associated with diphenhydramine in children, 2008-2015.

Palmer RB, Reynolds KM, Banner W, Randall Bond G, Kauffman RE, Paul IM, Green JL, Dart RC.

Clin Toxicol (Phila). 2019 May 7:1-8. doi: 10.1080/15563650.2019.1609683. [Epub ahead of print]

PMID:
31062642
9.

The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.

Dart RC, Bush SP, Heard K, Arnold TC, Sutter M, Campagne D, Holstege CP, Seifert SA, Lo JCY, Quan D, Borron S, Meurer DA, Burnham RI, McNally J, Garcia-Ubbelohde W, Anderson VE.

Ann Emerg Med. 2019 Sep;74(3):439-449. doi: 10.1016/j.annemergmed.2019.02.007. Epub 2019 Mar 27.

PMID:
30926190
10.

Brief report: Characterization of marijuana use in us college students by state marijuana legalization status as reported to an online survey.

Wang GS, Haynes C, Besharat A, Lait ML, Green JL, Dart RC, Roosevelt G.

Am J Addict. 2019 Jul;28(4):266-269. doi: 10.1111/ajad.12870. Epub 2019 Mar 22.

PMID:
30901123
11.

Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy.

Black JC, Bau GE, Rosen T, Cepeda MS, Wedin GP, Green JL, Dart RC.

Pain Med. 2019 Mar 16. pii: pnz031. doi: 10.1093/pm/pnz031. [Epub ahead of print]

PMID:
30877807
12.

Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.

Cicero TJ, Mendoza M, Cattaneo M, Dart RC, Mardekian J, Polson M, Roland CL, Schnoll SH, Webster LR, Park PW.

Postgrad Med. 2019 Apr;131(3):225-229. doi: 10.1080/00325481.2019.1585688. Epub 2019 Mar 19.

PMID:
30794760
13.

Causal inference for evaluating prescription opioid abuse using trend-in-trend design.

Dasgupta N, Schwarz J, Hennessy S, Ertefaie A, Dart RC.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):716-725. doi: 10.1002/pds.4736. Epub 2019 Feb 3.

PMID:
30714239
14.

Transition to two-bag intravenous acetylcysteine for acetaminophen overdose: a poison center's experience.

Hoyte C, Dart RC.

Clin Toxicol (Phila). 2019 Mar;57(3):217-218. doi: 10.1080/15563650.2018.1510127. Epub 2019 Jan 28. No abstract available.

PMID:
30689437
15.

Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children.

Green JL, Reynolds KM, Banner W, Bond GR, Kauffman RE, Palmer RB, Paul IM, Dart RC.

BMC Med Res Methodol. 2018 Dec 22;18(1):175. doi: 10.1186/s12874-018-0626-3.

16.

The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness.

Melandri D, Zlatareva I, Chaleil RAG, Dart RJ, Chancellor A, Nussbaumer O, Polyakova O, Roberts NA, Wesch D, Kabelitz D, Irving PM, John S, Mansour S, Bates PA, Vantourout P, Hayday AC.

Nat Immunol. 2018 Dec;19(12):1352-1365. doi: 10.1038/s41590-018-0253-5. Epub 2018 Nov 12.

PMID:
30420626
17.

Understanding multi-pill ingestion of prescription opioids: Prevalence, characteristics, and motivation.

Ellis MS, Cicero TJ, Dart RC, Green JL.

Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):117-121. doi: 10.1002/pds.4687. Epub 2018 Nov 9.

PMID:
30411819
18.

Consistency Between Opioid-Related Mortality Trends Derived From Poison Center and National Vital Statistics System, United States, 2006-2016.

Iwanicki JL, Severtson SG, Margolin Z, Dasgupta N, Green JL, Dart RC.

Am J Public Health. 2018 Dec;108(12):1639-1645. doi: 10.2105/AJPH.2018.304728.

19.

Medication history assessment in research: A randomized controlled trial comparing tablet-based (eMedHAT) versus structured interview (MedHAT).

Green JL, Anderson V, Dart RC, Heard K.

Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1356-1360. doi: 10.1002/pds.4665. Epub 2018 Oct 5.

PMID:
30289578
20.

Fewer adverse effects associated with a modified two-bag intravenous acetylcysteine protocol compared to traditional three-bag regimen in paracetamol overdose.

Schmidt LE, Rasmussen DN, Petersen TS, Macias-Perez IM, Pavliv L, Kaelin B, Dart RC, Dalhoff K.

Clin Toxicol (Phila). 2018 Nov;56(11):1128-1134. doi: 10.1080/15563650.2018.1475672. Epub 2018 May 24.

PMID:
29792347
21.

Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphone.

Lebin JA, Murphy DL, Severtson SG, Bau GE, Dasgupta N, Dart RC.

Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):25-30. doi: 10.1002/pds.4558. Epub 2018 May 15.

PMID:
29766592
22.

Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures.

Wang GS, Severtson SG, Bau GE, Dart RC, Green JL.

Pediatrics. 2018 Jun;141(6). pii: e20174232. doi: 10.1542/peds.2017-4232. Epub 2018 May 3.

23.

Trends in intentional abuse or misuse of benzodiazepines and opioid analgesics and the associated mortality reported to poison centers across the United States from 2000 to 2014.

Calcaterra SL, Severtson SG, Bau GE, Margolin ZR, Bucher-Bartelson B, Green JL, Dart RC.

Clin Toxicol (Phila). 2018 Nov;56(11):1107-1114. doi: 10.1080/15563650.2018.1457792. Epub 2018 Apr 3.

PMID:
29609498
24.

Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics.

Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC.

Drug Saf. 2018 Aug;41(8):787-795. doi: 10.1007/s40264-018-0660-4.

PMID:
29582394
25.

Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids.

Miller CJ, Dart RC, Katz NP, Webster LR.

J Opioid Manag. 2017 Nov/Dec;13(6):379-389. doi: 10.5055/jom.2017.0416. Review.

PMID:
29308585
26.

Do abuse deterrent opioid formulations work?

Dart RC, Iwanicki JL, Dasgupta N, Cicero TJ, Schnoll SH.

J Opioid Manag. 2017 Nov/Dec;13(6):365-378. doi: 10.5055/jom.2017.0415. Review.

PMID:
29308584
27.

Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.

Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, Green JL.

J Pain. 2018 Apr;19(4):439-453. doi: 10.1016/j.jpain.2017.11.007. Epub 2017 Dec 7.

PMID:
29224919
28.

Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations.

Argoff CE, Alford DP, Fudin J, Adler JA, Bair MJ, Dart RC, Gandolfi R, McCarberg BH, Stanos SP, Gudin JA, Polomano RC, Webster LR.

Pain Med. 2018 Jan 1;19(1):97-117. doi: 10.1093/pm/pnx285.

29.

Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.

Butler SF, Black RA, Severtson SG, Dart RC, Green JL.

J Subst Abuse Treat. 2018 Jan;84:42-49. doi: 10.1016/j.jsat.2017.10.010. Epub 2017 Oct 27.

PMID:
29195592
30.

Serum paracetamol-protein adducts in ambulatory subjects: Relationship to recent reported paracetamol use.

Heard K, Anderson VE, Lavonas EJ, Dart RC, Green JL.

Biomarkers. 2018 May;23(3):288-292. doi: 10.1080/1354750X.2017.1410857. Epub 2017 Dec 8.

PMID:
29179598
31.

Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.

Bucher Bartelson B, Le Lait MC, Green JL, Cepeda MS, Coplan PM, Maziere JY, Wedin GP, Dart RC.

Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1061-1070. doi: 10.1002/pds.4257. Epub 2017 Jul 31.

PMID:
28758289
32.

Optimising use of thiopurines in inflammatory bowel disease.

Dart RJ, Irving PM.

Expert Rev Clin Immunol. 2017 Sep;13(9):877-888. doi: 10.1080/1744666X.2017.1351298. Epub 2017 Jul 12. Review.

PMID:
28678626
33.

Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care.

Dart RC, Goldfrank LR, Erstad BL, Huang DT, Todd KH, Weitz J, Bebarta VS, Caravati EM, Henretig FM, Delbridge TR, Banner W, Schneider SM, Anderson VE.

Ann Emerg Med. 2018 Mar;71(3):314-325.e1. doi: 10.1016/j.annemergmed.2017.05.021. Epub 2017 Jun 29. Review.

34.

Treatment-Related Cardiovascular Outcomes in Patients with Symptomatic Subclavian Artery Stenosis.

Epperla N, Ye F, Idris A, Sakkalaek A, Liang H, Chyou PH, Dart RA, Mazza J, Yale S.

Cureus. 2017 May 19;9(5):e1262. doi: 10.7759/cureus.1262.

35.

Safety Profile of Cough and Cold Medication Use in Pediatrics.

Green JL, Wang GS, Reynolds KM, Banner W, Bond GR, Kauffman RE, Palmer RB, Paul IM, Dart RC.

Pediatrics. 2017 Jun;139(6). pii: e20163070. doi: 10.1542/peds.2016-3070. Epub 2017 May 4.

36.

Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings.

Buttram ME, Kurtz SP, Dart RC, Margolin ZR.

Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1083-1086. doi: 10.1002/pds.4230. Epub 2017 May 10.

PMID:
28493425
37.

Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.

Smith SM, Jones JK, Katz NP, Roland CL, Setnik B, Trudeau JJ, Wright S, Burke LB, Comer SD, Dart RC, Dionne R, Haddox JD, Jaffe JH, Kopecky EA, Martell BA, Montoya ID, Stanton M, Wasan AD, Turk DC, Dworkin RH.

J Pain. 2017 Nov;18(11):1287-1294. doi: 10.1016/j.jpain.2017.03.015. Epub 2017 May 4.

38.

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.

Dart RJ, Samaan MA, Powell N, Irving PM.

Clin Exp Gastroenterol. 2017 Mar 3;10:57-66. doi: 10.2147/CEG.S110547. eCollection 2017. Review.

39.

Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration.

Green JL, Bucher Bartelson B, Le Lait MC, Roland CL, Masters ET, Mardekian J, Bailey JE, Dart RC.

Drug Alcohol Depend. 2017 Jun 1;175:140-145. doi: 10.1016/j.drugalcdep.2017.01.039. Epub 2017 Mar 28.

40.

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States.

Iwanicki JL, Severtson SG, McDaniel H, Rosenblum A, Fong C, Cicero TJ, Ellis MS, Kurtz SP, Buttram ME, Dart RC.

PLoS One. 2016 Dec 9;11(12):e0167499. doi: 10.1371/journal.pone.0167499. eCollection 2016.

41.

Serum Acetaminophen Protein Adduct Concentrations in Pediatric Emergency Department Patients.

Heard K, Anderson V, Dart RC, Kile D, Lavonas EJ, Green JL.

J Pediatr Gastroenterol Nutr. 2017 Apr;64(4):533-535. doi: 10.1097/MPG.0000000000001459.

PMID:
27846064
42.

Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.

Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, Gilbert MK, Buttram ME, Dasgupta N, BucherBartelson B, Green JL, Dart RC.

Drug Alcohol Depend. 2016 Nov 1;168:219-229. doi: 10.1016/j.drugalcdep.2016.09.018. Epub 2016 Oct 3.

43.

Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments.

Di Marco Barros R, Roberts NA, Dart RJ, Vantourout P, Jandke A, Nussbaumer O, Deban L, Cipolat S, Hart R, Iannitto ML, Laing A, Spencer-Dene B, East P, Gibbons D, Irving PM, Pereira P, Steinhoff U, Hayday A.

Cell. 2016 Sep 22;167(1):203-218.e17. doi: 10.1016/j.cell.2016.08.030. Epub 2016 Sep 15.

44.

Evaluating electronic health record data sources and algorithmic approaches to identify hypertensive individuals.

Teixeira PL, Wei WQ, Cronin RM, Mo H, VanHouten JP, Carroll RJ, LaRose E, Bastarache LA, Rosenbloom ST, Edwards TL, Roden DM, Lasko TA, Dart RA, Nikolai AM, Peissig PL, Denny JC.

J Am Med Inform Assoc. 2017 Jan;24(1):162-171. doi: 10.1093/jamia/ocw071. Epub 2016 Aug 7.

45.

Salt Sensitivity of Blood Pressure: A Scientific Statement From the American Heart Association.

Elijovich F, Weinberger MH, Anderson CA, Appel LJ, Bursztyn M, Cook NR, Dart RA, Newton-Cheh CH, Sacks FM, Laffer CL; American Heart Association Professional and Public Education Committee of the Council on Hypertension; Council on Functional Genomics and Translational Biology; and Stroke Council.

Hypertension. 2016 Sep;68(3):e7-e46. doi: 10.1161/HYP.0000000000000047. Epub 2016 Jul 21. Review. No abstract available. Erratum in: Hypertension. 2016 Oct;68(4):e62.

PMID:
27443572
46.

The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC.

Clin Pharmacol Ther. 2016 Sep;100(3):275-86. doi: 10.1002/cpt.390. Epub 2016 Jun 22. Erratum in: Clin Pharmacol Ther. 2017 Apr;101(4):541.

47.

Accuracy of the Structured Medication History Assessment Tool (MedHAT) Compared with Recorded Real-Time Medication Use.

Heard K, Anderson VE, Dart RC, Green JL.

Pharmacotherapy. 2016 May;36(5):496-504. doi: 10.1002/phar.1750. Epub 2016 May 2.

PMID:
27029649
48.

Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.

Wiegand TJ, Le Lait MC, Bartelson BB, Dart RC, Green JL.

J Pain. 2016 Jun;17(6):745-52. doi: 10.1016/j.jpain.2016.02.015. Epub 2016 Mar 18.

PMID:
26996928
49.

Outcomes of Patients With Premature Discontinuation of the 21-h Intravenous N-Acetylcysteine Protocol After Acute Acetaminophen Overdose.

Lucyk SN, Yarema MC, Sivilotti ML, Johnson DW, Nettel-Aguirre A, Victorino C, Bailey B, Dart RC, Heard K, Spyker DA, Rumack BH.

J Emerg Med. 2016 Apr;50(4):629-37. doi: 10.1016/j.jemermed.2015.12.004. Epub 2016 Feb 15.

PMID:
26899513
50.

Diversion and Illicit Sale of Extended Release Tapentadol in the United States.

Dart RC, Surratt HL, Le Lait MC, Stivers Y, Bebarta VS, Freifeld CC, Brownstein JS, Burke JJ, Kurtz SP, Dasgupta N.

Pain Med. 2016 Aug;17(8):1490-6. doi: 10.1093/pm/pnv032. Epub 2015 Dec 14.

Supplemental Content

Support Center